H. Bai

F. Tang, Zhaoli Chen, Shuhang Wang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

541例女性晚期非小细胞肺癌患者的预后因素分析

H. Bai, M. Zhuo, J. Duan, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Malignant pleural effusion cell blocks are substitutes for tissue in EML4‐ALK rearrangement detection in patients with advanced non‐small‐cell lung cancer

Xianxin Li, X. Li, H. Bai, 2016, Cytopathology : official journal of the British Society for Clinical Cytology.

[The Association between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A meta-analysis.].

H. Bai, J. Duan, Zhijie Wang, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer

H. Bai, M. Zhuo, J. Duan, 2017, Oncotarget.

Correlation among Genetic Variations of c-MET in Chinese Patient with Non-Small Cell Lung Cancer

H. Bai, M. Zhuo, J. Duan, 2017 .

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

H. Bai, J. Duan, Zhijie Wang, 2020, Journal of Cancer.

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer

Si Li, M. Xiao, Dong-sheng Chen, 2022, Cell proliferation.

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer

X. Wang, Shuhang Wang, Y. Shao, 2020, EBioMedicine.

Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq

F. Tang, Lu Wen, Qingqing Li, 2022, Genome Medicine.

A metagenome association study of gut microbiome revealed biomarkers for chemotherapy efficacy in locally advanced and advanced lung cancer

H. Bai, J. Duan, Zhijie Wang, 2020 .

Proteomic analysis of plasma-derived exosomes identifies biomarkers that distinguish brain and liver metastasis in lung cancer patients.

H. Bai, Sini Li, chao wang, 2022, Cancer letters.

Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis

H. Bai, Y. Chai, J. Duan, 2022, Thoracic cancer.

The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study

H. Bai, J. Duan, Zhijie Wang, 2020, Cancer management and research.

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer

F. Tang, Qingqing Li, C. Gay, 2022, Signal Transduction and Targeted Therapy.

Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer

H. Bai, J. Duan, Zhijie Wang, 2022, Thoracic cancer.

Expression of ΔDNMT3B variants and its association with estrogen/progestogen receptor status in breast cancer

Shuhang Wang, H. Bai, M. Zhuo, 2009 .

[Individualized treatment recommendations for lung cancer patients at different stages of treatment during the outbreak of 2019 novel coronavirus disease epidemic].

H. Bai, J. Duan, Z. Zhao, 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma

H. Bai, J. Duan, L. Cai, 2022, Journal of oncology.

Clinical features of patients with lung adenocarcinomas harboring BRAF V600E mutations.

Shuhang Wang, H. Bai, M. Zhuo, 2013 .

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

X. Yi, Xiao Chen, Y. Guan, 2022, Cancers.

Prognostic significance of molecular characteristics of cerebrospinal fluid for non‐small cell lung cancer patients with leptomeningeal metastasis

Ning Li, H. Bai, J. Duan, 2019, Thoracic cancer.

Case Report: A New Subtype of Lynch Syndrome Associated With MSH2 c.1024_1026 Identified in a Chinese Family

H. Bai, Jie Wang, Zhengyi Zhao, 2022, Frontiers in Medicine.

A case of a new Lynch Syndrome variant with a deletion, c.1024_1026, in the MSH2 gene in a Chinese family

H. Bai, Jie Wang, Zhengyi Zhao, 2020 .

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Shuhang Wang, Jian Zhu, H. Bai, 2012, Journal of Experimental & Clinical Cancer Research.

Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.

Shuhang Wang, Hanxiao Chen, H. Bai, 2019, Lung cancer.

Predictive Value of Max’s Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors

H. Bai, Jie Wang, Sini Li, 2021, Frontiers in Cell and Developmental Biology.

Therapeutic Guidance of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-analysis

H. Bai, Guoqiang Wang, J. Duan, 2021, Journal of the National Cancer Center.

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

H. Bai, S. Cai, J. Duan, 2021, BMC Medicine.

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers

D. Carbone, Wei Zhao, G. Feng, 2021, Science Advances.

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma

H. Bai, Guoqiang Wang, S. Cai, 2020, Journal for ImmunoTherapy of Cancer.

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Jie He, Jianjun Zhang, Yanhua Tian, 2020, BMC Medicine.

Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer

Xueda Hu, Zemin Zhang, Fan Zhang, 2020, Cancer Immunology, Immunotherapy.

Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors.

Shuhang Wang, Junling Li, Yanhua Tian, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells

X. Xie, Shuhang Wang, Ruoyan Li, 2019, Clinical Cancer Research.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Jing Zhao, Guoqiang Wang, Jun Zhao, 2019, JAMA oncology.

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

T. Mok, Zemin Zhang, Shuhang Wang, 2018, Cancer research.

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Qinghua Zhou, H. Bai, M. Zhuo, 2013, PloS one.

Evolution and Genotypic Characteristics of Small Cell Lung Cancer Transformation in Non-Small Cell Lung Carcinomas

Yan Wang, Hanxiao Chen, Tiantian Gu, 2021, Journal of the National Cancer Center.

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

Shuhang Wang, G. Zhu, H. Bai, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

Jun-ling Li, Yan Wang, X. Hao, 2019, Investigational New Drugs.

Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations

Zemin Zhang, Zhirong Shen, Xiaodong Wang, 2015, Proceedings of the National Academy of Sciences.

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

Shuhang Wang, H. Bai, J. Duan, 2020, Frontiers in Immunology.

TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Shuhang Wang, Yanhua Tian, H. Bai, 2019, Cancer Immunology Research.

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies

H. Bai, J. Duan, Zhijie Wang, 2015, Thoracic cancer.

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs

H. Bai, Zhijie Wang, Jiachen Xu, 2022, Thoracic cancer.

Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review

H. Bai, Jie Wang, Sini Li, 2021, Translational lung cancer research.

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations

Shuhang Wang, Zhirong Shen, H. Bai, 2015, Scientific Reports.

Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer.

Wei Zhao, Shuhang Wang, Zhirong Shen, 2019, Cancer letters.

Impact of PD‐L1, transforming growth factor‐β expression and tumor‐infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors

H. Bai, J. Duan, Yu Sun, 2018, Thoracic cancer.

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Shuhang Wang, H. Bai, J. Duan, 2012, Journal of experimental & clinical cancer research : CR.

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

Shuhang Wang, H. Bai, M. Zhuo, 2015, Journal of Hematology & Oncology.

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

H. Bai, M. Zhuo, J. Duan, 2015, Thoracic cancer.

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

X. Wang, Shuhang Wang, Junling Li, 2020 .

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

H. Bai, J. Duan, Jun Zhao, 2016, Chinese journal of cancer.

Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non‐small cell lung cancer when treated with EGFR‐tyrosine kinase inhibitors

H. Bai, M. Zhuo, J. Duan, 2014, Thoracic cancer.

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

H. Bai, J. Duan, Zhijie Wang, 2023, Frontiers of Medicine.

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer

Shuhang Wang, Qinghua Zhou, H. Bai, 2013, PloS one.

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Shuhang Wang, Yilong Wu, H. Bai, 2012, Oncology.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

L. Mao, H. Bai, Jun Zhao, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib

H. Bai, Jie Wang, Jiefei Han, 2021, Translational oncology.

Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer

X. Wang, Shuhang Wang, H. Bai, 2010, Clinical Cancer Research.

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.

Shuhang Wang, S. Song, H. Bai, 2010, Lung cancer.

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

G. Zhu, H. Bai, C. Xue, 2012, OncoTargets and therapy.

Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment.

Ying Cheng, Yi-long Wu, Yuankai Shi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.

Shuhang Wang, Hanxiao Chen, H. Bai, 2017, Oncology letters.

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

R. Chen, Shuhang Wang, H. Bai, 2014, PloS one.

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI

Shuhang Wang, H. Bai, M. Zhuo, 2012, Thoracic cancer.

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

Qinghua Zhou, Li Mao, Jun Zhao, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.

J. Yu, H. Bai, J. Duan, 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Analysis of BIM (BCL‐2 like 11 gene) deletion polymorphism in Chinese non‐small cell lung cancer patients

H. Bai, J. Duan, Jun Zhao, 2014, Thoracic cancer.

Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer

T. Mok, Ping Yang, H. Bai, 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis.

H. Bai, Jie Wang, Sini Li, 2021, Lung cancer.

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer

H. Bai, M. Zhuo, J. Duan, 2016, Oncotarget.

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation

Zhirong Shen, H. Bai, Zhijie Wang, 2015, Thoracic cancer.

Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations

H. Bai, Jun Zhao, T. An, 2015, Thoracic cancer.

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Lai Wei, Shuhang Wang, Jian Zhu, 2012, Journal of experimental & clinical cancer research : CR.

[Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].

H. Bai, Mei-na Wu, Jie Wang, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

晚期非小细胞肺癌初始治疗后再次应用EGFR-TKI的疗效观察

H. Bai, Zhijie Wang, T. An, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Yibo Gao, F. Tan, Q. Xue, 2021, The Lancet. Oncology.

Tilianin inhibits the human ovarian cancer (PA-1) cell proliferation via blocking cell cycle, inducing apoptosis and inhibiting JAK2/STAT3 signaling pathway

H. Bai, S. Xia, F. Yu, 2021, Saudi journal of biological sciences.

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

H. Bai, J. Duan, Jie Wang, 2023, Frontiers in Oncology.

Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

H. Bai, Guoqiang Wang, J. Duan, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumour‐derived exosomes in liver metastasis: A Pandora's box

H. Bai, chao wang, Jie Wang, 2023, Cell proliferation.

Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis‐inhibiting pathway

H. Bai, Jie Wang, Xiran He, 2020, Thoracic cancer.

Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors

Ye Liu, Yang Du, H. Bai, 2022, Journal for ImmunoTherapy of Cancer.

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer

Hanxiao Chen, H. Bai, M. Zhuo, 2018, Thoracic cancer.

A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China

H. Bai, J. Duan, Zhijie Wang, 2010 .

Analyzing epidermal growth factor receptor mutation status changes in advanced non‐small‐cell lung cancer at different sampling time‐points of blood within one day

H. Bai, Jie Wang, Jin Wang, 2017, Thoracic cancer.

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer

L. Mao, Shuhang Wang, G. Feng, 2010, Medical oncology.

A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma

Shi Yan, Shaolei Li, Yue Yang, 2013, World Journal of Surgical Oncology.

High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy

H. Bai, J. Duan, Zhijie Wang, 2010 .

Programmed cell death‐ligand 1 (PD‐L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC)

Jun Zhao, H. Bai, M. Zhuo, 2016, Thoracic cancer.

Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.

H. Bai, M. Zhuo, J. Duan, 2014, Molecular and clinical oncology.

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.

J. Lee, Qing Wang, J. Zhao, 2019, JAMA oncology.

ERO1L Is a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment

H. Bai, Jie Wang, Sini Li, 2021, Frontiers in Immunology.

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis

H. Bai, Y. Chai, J. Duan, 2022, Journal of clinical medicine.

Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Zhaoli Chen, Jie He, J. Gu, 2018, Clinical Cancer Research.

Comprehensive Analyses and Immunophenotyping of LIM Domain Family Genes in Patients with Non-Small-Cell Lung Cancer

H. Bai, Lihui Liu, Sini Li, 2023, International journal of molecular sciences.

Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy

H. Bai, R. Wan, Zheng Liu, 2023, Frontiers in Immunology.

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Jie Tian, Yanhua Tian, Yang Du, 2020, Journal for ImmunoTherapy of Cancer.

HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients

M. Ye, H. Bai, Jie Wang, 2019, Theranostics.

Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer

Wei Zhao, Shuhang Wang, Hanxiao Chen, 2018, Clinical Cancer Research.

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.

Hanxiao Chen, H. Bai, Yahui Tian, 2022, Future oncology.

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Shuhang Wang, H. Bai, J. Duan, 2012, Journal of experimental & clinical cancer research : CR.

HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients

M. Ye, H. Bai, Jie Wang, 2019, Theranostics.

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment

Yanhua Tian, H. Bai, J. Duan, 2023, Thoracic cancer.

MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama

H. Bai, J. Duan, Liangliang Cai, 2023, BMC Cancer.

A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression

H. Bai, J. Duan, Zhijie Wang, 2009 .

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments

H. Bai, M. Zhuo, J. Duan, 2017, Thoracic cancer.

An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type.

X. Liu, H. Bai, J. Duan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A folate/RGD‐dual‐functionalized mesoporous silica nanoparticles targeting GABA‐p38 MAPK‐MRTFs/SRF signaling pathway in rheumatoid arthritis

Chunguo Wang, H. Bai, Ke Hou, 2021, Clinical and translational medicine.

KRAS mutants to regulate PD-L1 expression through NF-ƘB and HIF-1α pathways in non-small cell lung cancer cells.

H. Bai, Jie Wang, R. Guo, 2017 .

Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer.

H. Bai, J. Duan, T. An, 2011, Journal of Clinical Oncology.

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

G. Zhu, H. Bai, C. Xue, 2012, OncoTargets and therapy.

EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值

H. Bai, Mei-na Wu, Jie Wang, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy

H. Bai, J. Duan, Zhijie Wang, 2023, Cell reports methods.

Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines

H. Bai, J. Duan, Zhijie Wang, 2023, Journal of the National Cancer Center.

[The detection by denaturing high performance liquid chromatography of epidermal growth factor receptor mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer].

H. Bai, J. Duan, Jun Zhao, 2008, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.